CSIMarket
 


Ionis Pharmaceuticals Inc  (IONS)
Other Ticker:  
 

Cumulative Ionis Pharmaceuticals Inc's Total Debt to Equity for Trailing Twelve Months Period

IONS's Total Debt to Equity for Trailing Twelve Months Period and Total Debt, Equity growth


Select the Comparisons : Select the Ratio:

IONS Total Debt to Equity for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Equity Growth -38.1 % -55.54 % -36.95 % 7.98 % 7.22 %
Y / Y Total Debt Growth -4.63 % -17.33 % -6.92 % -14.74 % -8.03 %
Total Debt to Equity for Trailing Twelve Months Period 1.4 1.25 1.1 1 1.05
Total Ranking # 1727 # 2422 # # 2496 # 2722
Seq. Equity Growth 22.58 % -35.17 % -15.07 % -8.3 % -11.96 %
Seq. Total Debt Growth 15.46 % -11.11 % 0.12 % -7.18 % 0.08 %


Total Debt to Equity for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to net new borrowings of 15.46%, Total Debt to Equity for Trailing Twelve Months Period improved to 1.4, above Ionis Pharmaceuticals Inc's average Total Debt to Equity for Trailing Twelve Months Period.
Total Debt to Equity for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Major Pharmaceutical Preparations industry 76 other companies have achieved lower Total Debt to Equity for Trailing Twelve Months Period than Ionis Pharmaceuticals Inc. While total ranking remained unchanged compare to previous quarter at no. .

What is Debt to Equity Ratio?
IONS Charts and Quotes
Total Debt to Equity IONS in the most recent quarter
Total Debt to Equity for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 77
Sector # 210
S&P 500 # 1810


Total Debt to Equity for Trailing Twelve Months Period Statistics
High Average Low
2.31 0.6 0
(Sep 30 2017)   (Jun 30 2017)




Companies with similar average Total Debt to Equity for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Total Debt to Equity for Trailing Twelve Months Period
Soligenix inc   3.76 
Puma Biotechnology Inc   3.69 
Collegium Pharmaceutical Inc   3.68 
Aslan Pharmaceuticals Limited  3.55 
Alimera Sciences Inc   3.49 
Avadel Pharmaceuticals Plc  3.32 
Harrow Inc   3.32 
Amicus Therapeutics inc   2.65 
Morphosys Ag  2.59 
Bioxcel Therapeutics Inc   2.46 
Therapeuticsmd Inc   2.44 
Teva Pharmaceutical Industries Limited  2.43 
Travere Therapeutics Inc   2.21 
Bullfrog Ai Holdings Inc   2.16 
Oncosec Medical Incorporated  2.08 
Sarepta Therapeutics Inc   2.07 
Eli Lilly And Company  1.89 
Ascendis Pharma A  1.83 
Phibro Animal Health Corporation  1.74 
Jazz Pharmaceuticals Plc  1.71 
Clene Inc   1.71 
Earth Science Tech Inc   1.50 
Zoetis Inc   1.45 
Evoke Pharma Inc   1.44 
Sunwin Stevia International Inc.  1.44 
Ionis Pharmaceuticals Inc  1.33 
Bristol myers Squibb Company  1.30 
Ocular Therapeutix Inc   1.28 
Aveo Pharmaceuticals Inc   1.26 
Arcutis Biotherapeutics Inc   1.25 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com